MediXall Group, Inc. Has Hit Significant Milestones and Now is Ready to Expand
FORT LAUDERDALE, FL., April 11, 2018 (GLOBE NEWSWIRE) -- -- MediXall Group Inc., (OTCQB: MDXL), a technology and innovation-driven organization structured to bring effective change to the U.S. Healthcare Industry, announced today that several significant milestones have been completed. Over the past year, MediXall has made significant progress on the Company’s strategic initiatives by achieving the following: MediXall Group, Inc. Announces Appointments to Medical Advisory Board
Launched MediXall Platform
In March 2018, we completed development of the MediXall Healthcare Marketplace and initiated a controlled launch in South Florida, specifically in the counties of Palm Beach, Broward, and Miami Dade. The South Florida launch consists of a select group of MediXall early adopters who completed the onboarding process and were approved by the credentialing committee. With MediXall’s 5,500+ registered healthcare providers continuing to complete their legal agreements and the subsequent process of credentialing, the full launch with all medical services available is on track for the second quarter of 2018. https://globenewswire.com/news-release/2018/04/11/1468497/0/en/MediXall-Group-Inc-Has-Hit-Significant-Milestones-and-Now-is-Ready-to-Expand.html
Ft. Lauderdale, Fla., Feb. 01, 2018 (GLOBE NEWSWIRE) -- MediXall Group Inc., (OTCQB:MDXL), a technology and innovation-driven organization structured to bring effective change to the U.S. Healthcare Industry, is pleased to announce that the company has added three medical doctors to the Medical Advisory Board and Credentialing Committee. Dr. Winston Marshall, MD, FACC (Denison, TX), Dr. John DeLuca, MD, DC, (Palm Beach, FL), and Dr. Kenneth Janson, MD, FACS (Boca Raton, FL), are published leaders in their fields of expertise as well as practicing physicians.
Michael Swartz, VP of Operations of MediXall Group, said, "We are assembling a team of Advisors that will guide MediXall to provide powerful solutions to the challenges experienced by practitioners, suppliers, and consumers in the Healthcare Industry. Dr. Marshall, Dr. DeLuca, and Dr. Janson are terrific individual leaders with prestigious careers and significant healthcare experience. Each will be a tremendous asset to MediXall as we continue to drive expansion in Florida, begin our nationwide roll-out, and pursue growth opportunities leveraging the strength of our Healthcare Ecosystem. We've also made it a priority to fully credential our providers to industry standards and are proud to have three world-class doctors join the team to help us deliver on this priority. We believe that our Healthcare Marketplace Platform should be no different than traditional healthcare in meeting quality of care standards set by the industry and delivering care to patients that they can trust."
With MediXall's commitment to promoting the highest level of quality care for its users, practitioners who join the MediXaid Provider Network must undergo a rigorous process called credentialing and only upon approval by the Credentialing Committee will a provider be able to start providing services through our Healthcare Marketplace Platform. The MediXall Credentialing Committee is responsible for reviewing the qualifications of candidates for the MediXaid Provider Network. Members of the Committee hold a Review meeting monthly to evaluate new providers for approval. MediXall is committed to its credentialing and suitability screening of all practitioners on its platform. Management feels strongly this will lead to the public having total confidence when they are comparing apple to apple healthcare providers.
Dr. Winston S. Marshall is an Interventional Cardiology Specialist in Denison, Texas. Dr. Marshall serves as Vice-President and Physician of Interventional Cardiology at Sherman Cardiovascular Care Associates. His Professional Organizations include being a Fellow, American College of Cardiology, an American College of Cardiology Member, a member of the American Medical Association, Texas Medical Association, American Society of Nuclear Cardiology, Grayson County Medical Society and the Dallas County Medical Society. He is an active staff member at the Wilson N. Jones Medical Center in Sherman, Texas where he has held Committee and Leadership Roles.
Dr. John DeLuca is a Diplomate of the American Board of Internal Medicine and the National Board of Chiropractic Examiners, and has obtained certifications in Hyperbaric Medicine, Pain Management, Nutrition, Strength and Conditioning, and Manipulation Under Anesthesia. He is a member of the Age Management Medicine Group, the Institute of Functional Medicine, the American College for the Advancement of Medicine, Hyperbaric and Undersea Medical Society. In addition to Internal and Hyperbaric Medicine, Dr. DeLuca's professional focus includes maximizing hormone and neurological functioning, Age Management and Regenerative Medicine, Detoxification and Chelation Therapy, Sports Medicine and Weight Loss, as well as promoting Prevention through Personal Lifestyle Medicine.
Dr. Kenneth Janson is a Fellow of the American College of Surgeons, a former US Air Force Surgeon, a Urologic Surgeon and a certified Age Management Physician. He is a member of the Board of Governors, Tulane University School of Medicine, and a frequent featured speaker at Age Management Medical Group National conferences. He has presented at the World Congress on Age Management Medicine on the topics of Decreasing the Risk of Cognitive Decline with Hormone Optimization, and Long Term Use of Testosterone: Balancing the Risks and Rewards in Patients with Cardiovascular Disease, BPH, and Prostate Cancer. Dr. Janson brings his extensive experience in clinical science and evidence-based medicine to the field of age management to provide a comprehensive treatment and prevention program to his patients. He combines the best of traditional medicine with clinically proven, state-of-the-art methods based on the latest techniques and research.
If you would like to preview the MediXall Healthcare Platform, please contact the company.
About MediXall Group, Inc.
MediXall Group is a technology and innovation-driven organization purposefully designed and structured to bring effective change to the U.S. healthcare industry that is actively trading on the OTCQB under the symbol "MDXL." The Company believes its revolutionary approach will help drive much needed change that it envisions is needed in the current healthcare system. The mission of the MediXall Group is to revolutionize the medical industry by improving communication; providing better technology and support services; and enabling more efficient, cost-effective healthcare for the consumer. By approaching the healthcare ecosystem as a whole, MediXall creates, invests and incubates companies that embody its mission statement. MediXall's first acquisition was MediXaid®, a developing cloud-based software platform that promises to revolutionize the way people purchase healthcare goods and services.
About MediXall Healthcare Platform
The first product MediXall is developing is the MediXall Healthcare Platform, which is on schedule for a first quarter 2018 launch. The MediXall Platform is a new generation healthcare marketplace platform to address the growing need of self-pay and high deductible consumers for greater transparency and price competition in their healthcare costs. With MediXall.com, patient/clients find price transparency and the ability to make informed choices based on price, location and schedule for requested medical products and services. In this era of rapidly increasing deductibles and healthcare costs, the cloud-based MediXall platform is designed to be transformational and disruptive to traditional methods of medical care and provisioning of medical services to the consumer.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company's current plans and expectations, as well as future results of operations and financial condition. Specifically, the Company's ability to raise additional capital, execute its business plan and strategy, sustain or increase gross margins, achieve profitability and build shareholder value are forward looking statements. A more extensive listing of risks and factors that may affect the Company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the Company with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact Michael Swartz, VP of Operations MediXall Group, Inc. Phone: (954) 908-3481 Email: firstname.lastname@example.org MEDIXALL GROUP’S FIRST PROJECT – The MEDIXAID Platform